Candida species are regular commensal in humans, but-especially in immunocompromised patients-they represent opportunistic pathogens giving rise to systemic infection. The aim of the present work was to isolate and characterize for their antifungal profile Candida species from different body sites and to analyze the biofilms produced by C. albicans and C. glabrata isolates. Eighty-one strains of Candida species from 77 patients were identified. Epidemiological study showed that the most isolated species were C. albicans (44), C. glabrata (13) and C. parapsilosis (13) mainly from Hematology, Infectious Diseases, Medicine, Neonatology and Oncology Divisions, the majority of the biological samples were swabs (44) and blood cultures (16). The analysis of the biofilm formation was performed at 24 and 48-hours comparing resistant and susceptible strains of C. albicans to resistant and susceptible strains of C. glabrata. Candida albicans has a greater ability to form biofilm compared to C. glabrata, both in the susceptible and resistant strains reaching maturity after 24 hours with a complex structure composed of blastospores, pseudohyphae, and hyphae embedded in a matrix. On the contrary, C. glabrata biofilm was composed exclusively of blastospores that in the resistant strain, after 24 hours, were organized in a compact multilayer different to the discontinuous structure observed in the susceptible analyzed strains. In conclusion, the increasing of the incidence of Candida species infection together with their emerging drug resistance also related to the biofilm forming capability underline the need to monitor their distribution and susceptibility patterns for improving the surveillance and for a correct management of the infection.
Introduction
Candida species are commensals of the skin, the mucosa or gastrointestinal tract of 30-50% of healthy subjects, but they can also represent opportunistic pathogens able to express severe infections involving major body organs. [1] [2] [3] In these last decades, the increasing of patients susceptible to invasive candidiasis is related to the larger number of immunocompromised hosts, 4 the widespread use of indwelling medical devices and invasive techniques, 5, 6 the prolonged hospitalization in the intensive care units (ICU) and the misuse of broad spectrum antimicrobial agents. 7, 8 Moreover, candidemia, considered as bloodstream infection associated to Candida species, represents one of the major cause of severe diseases in hospitalized patients responsible for notably mortality rate. 9 Candida albicans represents the main pathogen, isolated in the 50-70% of the above mentioned cases and its success in human host interaction depends on the wide number of strategies used for colonization/infection, which can be related to its genetic, biochemical morphological resilience. 10, 11 More recently, other species such as non-Candida albicans Candida (NCAC) species, were notably detected and their emerging role in human infections became of interest. 12, 13 This increased number of NCAC species identified, can reflect both the improvement of diagnostic methodologies and their major capability to persist in the host in respect to C. albicans. Moreover, in the human mixed candidiasis, the NCAC species cause a high resistant profile to antifungal drugs. 12 .
Moreover, the well-documented rapid development of resistance to antifungals, such as azoles or echinocandins, contributes to the interest against this emerging species in terms of developing new strategies for yeast eradication. 14, 15 Among these species, C. glabrata has been detected as a nosocomial pathogen in mucosal and systemic infections and its major incidence can be correlated to immunosuppressive and antimicrobial treatments. 12, 16 From epidemiological studies, C. albicans and C. glabrata represent the most common species found in different settings.
In particular, the greater number of strains were isolated from blood, abdomen, lung, skin/soft tissue, urine, and fecal/rectal swabs. 15, 16 As for all microorganisms capable to form biofilms, Candida species form a well-structured biofilm, which represents a key factor for tenacious adhesion to the host tissues evading the immune system and for developing antifungal tolerance. 17, 18 In this context, Candida species sessile population adds more skills in respect to the planktonic counterpart to persist in the host developing a multifactorial system of antifungal tolerance. 19 In particular, C. albicans biofilm shows stronger resistance to azoles through the upregulation of efflux pumps that plays an additive role in contributing to resistance in early phase of biofilm formation. 20 In a recent work, Ferreira et al. 21 found that all Candida species isolated from hospitalized patients were capable to form biofilm that was directly related to fungal virulence being both more tolerant to antifugal drugs and contributing to the pathogenesis of superficial and systematic candidiasis. 22 Consequently, in the clinical practice, a more species specific diagnosis is recommended to better identify the Candida species responsible for infection and for therapy management. Based on these remarks, in this study we collected samples from different body sites to identify Candida species and to assess their antifungal pattern against the most common drugs used in therapy. Strains were collected and analyzed by Microbiology Laboratory of Pescara Hospital in Central Italy, during a period of 4 months. Moreover, the capability of biofilm formation of the two most frequent isolated species, C. albicans and C. glabrata, considered of interest in human candidiasis, were studied and compared to their antifungal profile.
Materials and methods

Sample collection and antifungal susceptibility tests
A total of 81 strains were isolated from 77 positive patients for Candida spp. with clinical signs of infections. Candida species were identified and characterized at the Microbiology Laboratory of Pescara Hospital, in Central Italy (Abruzzo) from October 2014 to January 2015. Epidemiological features of Candida species were recorded and information regarding the sex and age of the patients were also provided. Patients gave their written informed consent for this study. Privacy and anonymity of all participating subjects were carefully respected. The clinical reason of sample collection was to define both the distribution of C. albicans and the emerging NCAC species among clinical Candida spp. isolates in the hospital divisions and their susceptibility profiles for the correct management of Candida spp. infections
Isolates were grown as yeast on Sabouraud agar medium (SAB) (OXOID, Milan, Italy) for 24 hours at 37
• C, were identified by the morphologic aspect of colonies and by biochemical identification by using the automated Vitek 2 YST-ID system (BioMerieux, Marcy L'Etoile, France). 23 The antifungal susceptibility test for all 81 Candida species was determined by using ASTYS01 kit on Vitek 2 system. The Vitek 2 cards contained serial twofold dilutions of flucytosine-5FC (concentration range: from 1 to 64 μg/ml), fluconazole-FLC (concentration range: from 1 to 64 μg/ml), voriconazole-VOR (concentration range: from 0.12 to 8 μg/ml), micafungin-MFG (concentration range: from 0.06 to 4 μg/ml) and amphotericin B-AMB (concentration range: from 0.25 to 16 μg/ml). Standard operative procedures were followed as described by the manufactures. 23 The antifungal susceptibility results obtained from Vitek 2 system for all isolated yeasts were compared to the EUCAST protocol 24 for all C. glabrata (13) and C.
albicans (44) isolates. The EUCAST breakpoint values were used to define the Candida species susceptibility profile: fluconazole-FLC (susceptible ≤ 2 μg/ml, resistant > 4 μg/ml, for C. albicans; susceptible ≤ 0.002 μg/ml, resistant > 32 μg/ml for C. glabrata), voriconazole-VOR (susceptible ≤ 0.12 μg/ml, resistant > 0.12 μg/ml for C. albicans and C. glabrata), amphotericin B (susceptible ≤ 1 μg/ml, resistant > 1 μg/ml for C. albicans and C. glabrata) 25 micafungin-MFG (susceptible ≤ 0.25 μg/ml, resistant > 0.5 μg/ml for C. albicans; susceptible ≤ 0.06 μg/ml, resistant > 0.12 μg/ml for C. glabrata). 26 For flucytosine, were used the CLSI breakpoints (susceptible ≤ 4 μg/ml, resistant ≥ 32 μg/ml for C. albicans and C. glabrata).
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For storage, colonies were subcultured in Trypticase soy broth (TSB, OXOID) for 24 hours at 37
• C. Subsequently, the cells were maintained at −80 • C in cryovials containing TSB, plus 10% of glycerol (OXOID). Candida albicans ATCC 10231 and C. glabrata ATCC 2001 were included as reference controls. For the biofilm studies, strains were collected in the Microbiology Laboratory of the Department of Pharmacy, University "G. d'Annunzio", Chieti-Pescara, Chieti, Italy.
Biofilm formation and biomass evaluation
For experiments, 13 C. albicans and 13 C. glabrata strains were studied; among them were included C. albicans 2R, C. albicans 32R and C. glabrata 21R that were the strains expressing resistance to at least one antifugal used for susceptibility tests; the others analyzed strains were susceptible to all detected drugs.
Candida albicans ATCC 10231 and C. glabrata ATCC 2001 were included as reference controls.
For biofilm formation, the colonies of C. albicans and C. glabrata not older than 3 days were recovered by SAB and grown in Roswell Park Memorial Institute medium (RPMI 1640, OXOID) plus 2% glucose (Sigma Aldrich) at 37
• C for 24 hours. 28 The broth cultures (200 μl) standardized at an optical density at 600 nm (OD 600 ) of 0.15 (corresponding to a concentration of ∼ 5 × 10 6 cfu/ml) were dispensed into 96-well polystyrene flat-bottomed microtiter plates (Nunclon Delta 96-well MicroWell Plate, Thermo Scientific, Rochester, NY, USA) and incubated both for 24 and 48-hours at 37
• C. After 24 hours of incubation the nonadherent C. albicans and C. glabrata cells were removed and the biomass production was quantified. For 48-hours biofilm, after 24 hours of incubation, 100 μl of surnatant were removed from each well, and 100 μl of RPMI 1640 plus 2% glucose were replaced for additional 24 hours of incubation. Subsequently, non-adherent C. albicans and C. glabrata cells were removed and the biomass production was evaluated.
For the biomass quantitative measurements, the crystalviolet staining method was used. 29 Briefly, the planktonic phase was removed from each well and the sessile fungal population was rinsed with 200 μl of H 2 O sterile, fixed by air drying and stained with 200 μl of crystal violet 0.1% (w/v) for 2 min. The stained biofilms were rinsed with 100 μl of H 2 O sterile, air dried, and eluted with 200 μl with EtOH. The optical density was measured at 595 nm using a microplate reader (SAFAS, Munich, Germany).
Each assay was performed in duplicate for three independent experiments.
Fluorescence microscopy assay
To visualize the extracellular polymeric substances (EPS) of the biofilms matrix, rhodamine-labelled Concanavalin A (rhodamine-conA) (Vector Laboratories, Burlingame, CA, USA), which specifically binds to d-(+)-glucose and d-(+)-mannose groups on EPS, was used. All strains of C. albicans and C. glabrata chosen for biomass evaluation, were considered in this analysis. For each studied strain, 1 ml of standardized broth culture was dispensed into 24-well polystyrene microtiter plates (Nunclon Delta MicroWell Plate, Thermo Scientific, Rochester, NY, USA) with seeded microscope coverslips. After 24 and 48-hours of incubation, the planktonic phase was removed from each well and the sessile fungal population was washed with 1 ml of PBS twice and stained with 500 μl of the rhodamineconA (10 μg/ml) solution; after 30 min of incubation in the dark at room temperature, the excess staining solution was removed and rinsed with 1 ml of PBS and examined under fluorescence Leica 4000 DM microscope (Leica Microsystems, Milan, Italy). Images were recorded at an excitation of 514 nm and an emission wavelength of 600 ± 50 nm.
Scanning electron microscopy (SEM) evaluation
Biofilms at 24 and 48-hours of all strains of C. albicans and C. glabrata chosen for biomass evaluation were observed by SEM to evaluate the morphology and cellular organization. For each studied strain, 1 ml of 0.15 OD 600 standardized cultures, was dispensed in 24-well plates containing sterile polystyrene disks and incubated both for 24 and 48-hours at 37
• C. For 48-hours biofilm, after 24 hours of incubation, 500 μl of surnatant were removed and 500 μl of RPMI 1640 + 2% glucose were added for an additional 24 hours of incubation. For SEM observation, biofilms produced at 24 and 48-hours on polystyrene disks were fixed in a 2% solution of glutaraldehyde in 0. 
Statistical analysis
The measurement data related to absorbance values of biofilm biomass were normally distributed. The results were expressed as average and standard deviation of OD 595 values of three independent experiments (mean value ± SD). Probability levels of <0.01 were considered statistically significant. Student t test and one-way analysis of variance (ANOVA) were used to compare the differences among the biofilm biomass. Moreover, we assumed a null hypothesis (HO) that C. albicans and C. glabrata produced an equal biofilm biomass, in time.
Results
Among the biological samples collected, between October 2014 and January 2015, 81 strains of Candida species coming from 77 patients were identified. In Table 1 shown are the results of the epidemiological study. Candida species were isolated mostly in Female (62%) in respect to Male (38%) and were prevalent in 26-50 and 51-75 age groups.
Among the collected yeasts, five of them were isolated from newborns, two from mouth and the other three from blood cultures (not shown). The main Candida species isolated were C. albicans (44), C. glabrata (13) and C. parapsilosis (13) . The majority of the isolates were recovered from swabs (44), blood cultures (16), urine (10), and sputum (5).
The hospital divisions most affected by Candida species infections, excluding external patients, were hematology, infectious diseases, medicine, neonatology, and oncology.
To define the antifungal resistance of Candida species recovered, susceptibility patterns were performed ( Table 2 ). All isolates displayed full susceptibility to 5FC, AMB and MFG, whereas two strains of C. albicans were resistant to FLC (4.54%) and one of them to VOR (2.27%); one strain of C. glabrata expressed resistance to FLC (7.69%). The patterns of susceptibility were evaluated using two different methodologies (Vitek 2 system and EUCAST protocol) that expressed similar results.
The topic of this study was also to study the biofilm produced by C. albicans and C. glabrata and compare it with their antifugal resistance.
For the comparisons, C. albicans 2R (resistant to FLC and VOR), C. albicans 32R (resistant to FLC), C. glabrata 21R (resistant to FLC), 11 strains of C. albicans and 12 C. glabrata, susceptible to all antifungals tested in the study, were chosen and analyzed for their biomass production through crystal violet stain and characterized for their different biofilm formation. Candida albicans 2R and C. albicans 32R were isolated from sputum and urine in the hematology and dialysis divisions, respectively. Candida glabrata 21R was isolated from a sample of urine in intensive care division. obtained for each C. albicans and C. glabrata clinical strain detected, respectively. At 24 hours, as shown in Figure 1 , C. albicans (resistant and susceptible clinical strains) expressed a significant greater ability to form biofilm compared to the respective C. glabrata strains (C. albicans vs. C. glabrata resistant strains, P = .002). Similar significance was recorded comparing the respective reference strains after 24 hours (C. albicans ATCC 10231 vs. C. glabrata ATCC 2001, P = .001). By one-way ANOVA, the differences among both C. albicans 2R and all susceptible C. albicans strains and C. glabrata 21R and all C. glabrata susceptible strains used for this analysis, were resulted also significant (see boxes 1 and 2).
In particular, C. albicans 2R displayed a mature biofilm after 24 and 48-hours with absorbance values of 1.87 ± 0.08 and 0.54 ± 0.06 (OD 595 ), respectively, that were significantly higher than susceptible strains. At 24 hours, analogous significance was recorded for C. glabrata In particular, in box 1 C. albicans 2R at 24 hours, § and at 48-hours, # was more biofilm producer than all susceptible strains; in box 2, C. glabrata 21R at 24 hours, * was more biofilm producer than all susceptible strains.
21R biofilm with absorbance value of 0.54 ± 0.10 (OD 595 ) compared to susceptible strains. Representative images of C. albicans resistant and susceptible strains (2R and 9S), were shown in Figure 2A and B, with a dense structure spatially organized in complex comprising a wide number of blastospores combined to hyphae and pseudohyphae, which were more abundant in the susceptible strains. Moreover, these cells were embedded in the extracellular matrix that was strongly recorded through the Con-A staining in C. albicans 2R resistant strain (Fig. 3A) in respect to C. albicans 9S susceptible (Fig. 3B) , both after 24 hours and 48-hours. Candida albicans 48-hours biofilm biomass, both in the resistant and susceptible strains, was significantly reduced in respect to the corresponding 24-hours biofilm ( Fig. 1) with aged cells and granulations (Fig. 2C, D, and  inserts) , that schemed wrapped in a mucilaginous coating; the biomass quantification was of 0.54 ± 0.06 and 0.39 ± 0.04 (OD 595 ) for resistant strains (2R and 32R) and of 0.29 ± 0.03 (mean values of OD 595 of the 11 isolates), respectively.
At 48-hours, C. albicans reference and resistant strains expressed a major capability to form biofilm compared to the C. glabrata reference and resistant strains (C. albicans vs. C. glabrata reference strains, P = .001; C. albicans 2R vs. C. glabrata 21R, P = .002). In addition, at 48-hours, the difference between the mean values of biofilms of C. albicans resistant and susceptible strains was significant with a P value of .003 (Fig. 1 ). This significant difference was confirmed by one-way ANOVA, comparing C. albicans 2R to all susceptible strains, but not for strain 32R (Fig. 1, box  1) .
For the 48-hours C. glabrata biofilms, no significant differences were recorded among resistant and the susceptible strains (Fig. 1, box 2) .
The C. glabrata biofilm in each observation (fluorescence and SEM) was constituted exclusively of thin yeast cells that, after 24 hours, in the resistant strain (21R) were organized in compact intimate multilayer together with noncolonized areas (Fig. 2E and insert) ; in contrast, in the susceptible strain (47S), yeast cells were clustered in a discontinuous structure (Fig. 2F) . At 48-hours, both C. glabrata resistant (21R) and C. glabrata susceptible (47S) strains, displayed a similar structure with thin aged yeast cells (Fig. 2G and  H) . The analysis of polysaccharides detected by using Con-A staining revealed a major extracellular matrix for both C. glabrata resistant and susceptible strains after 24 hours, in respect to the 48-hours detection (Fig. 3E-H ).
Discussion
In this study, we have isolated, identified, and characterized strains of Candida species from biological samples collected from the "Santo Spirito" Hospital of Pescara, from October 2014 to January 2015, defining the susceptibility profile to common antifungal drugs used in therapy.
In recent decades, Candida species have become frequent human pathogens, capable of causing multiple superficial and deep infections particularly of the skin, mucous membranes and the gastrointestinal tract. Although Candida species are generally not very aggressive, they may cause infection if the immune system is impaired or if an environmental niche becomes available. In this perspective, we focused part of our study on epidemiology features of Candida species. The epidemiological study showed that the most isolated species were C. albicans, C. glabrata and C. parapsilosis, these latter belonging to NCAC species that, in recent years, have caused many systemic candidiasis, that for C. glabrata were even fatal. 30, 31 In this study, the capability of Candida species to cause systemic candidiasis was demonstrated by their presence in blood cultures and in central venous catheter. These results underline the increasing role of these yeasts in invasive diseases which can be attributed not only to C. albicans but also to NCAC species emerging as pathogens. In fact, from blood cultures among the 16 isolates, together with seven C. albicans strains identified, were two strains of C. glabrata, three strains of C. parapsilosis, and four strains of C. tropicalis. As also reported by Serrano-Fujarte et al., 32 C. albicans remains the most isolated species from blood cultures, since this species colonizes sites of body rich of glucose such as blood. Therefore, our data confirmed that C. albicans remains the most involved yeast in human invasive infection, and that NCAC species begin to be recognized as pathogens in the hematological setting. Moreover, invasive medical procedures, the use of broad spectrum antibiotics and corticosteroids and the spread of immunodeficiency diseases were all associated with a dramatic increase of incidence of a harmful fungal diseases, due to resistant strains that were inherently difficult to treat. 33, 34 Among the isolated Candida species, we found that two strains of C. albicans were resistant to FLC and one of them also to VOR and one strain of C. glabrata displayed resistance against FLC. In particular, the diffusion of FLC resistance can be considered an example of C. albicans microevolution during the life-long association with its human host. [35] [36] [37] In a first evaluation of these results, the resistance rate against the most common antifungal drugs used in therapy did not seem to be a serious problem in the clinical management, but these data, combined to the detected capability to form biofilm, revealed in 13 C. albicans and all C. glabrata isolated clinical strains, displayed the need to improve surveillance.
Regarding the biofilm analysis after 24 h, resistant and susceptible C. albicans strains produced a significant more abundant biofilm biomass than all tested C. glabrata strains, rejecting the hypothesis under 24 h. On the contrary, at 48 h no differences in terms of biomass produced by the two studied Candida spp. were displayed.
From qualitative analysis, the biofilm of C. albicans showed a dense biofilm, spatially organized and characterized by a multitude of blastospores, hyphae and pseudohyphae partially embedded in the extracellular matrix, that, as also demonstrated by Costa et al., contributes to the increase of the C. albicans adhesion. 28 This multilayered structure represents a valid architecture for supporting the exopolymeric substances produced around the cells.
Our results indicate that there are strong differences between C. albicans and C. glabrata biofilm structure and, in fact, biofilms of C. glabrata are composed exclusively of rather compact, small and irregular blastospores in an extracellular matrix. As previously shown 38 and confirmed in our study, C. glabrata produces an established biofilm during the time in respect to C. albicans that forms more biofilm biomass at 24 hours, with a significant reduction at 48-hours that could favor the cell dispersion. This last behavior, also described by Sellam et al., emphasizes the C. albicans capability to detach themselves from the sessile community for the dissemination. 39 Regarding the comparative analysis among each susceptible and resistant strains, within the limits of the present study, we found an interesting correlation between C. albicans and C. glabrata biofilm formation and their antifungal profile.
As previously reported by Vavala et al., C. albicans strain resistant to FLC was able to form more biofilm in respect to susceptible strain, due to the increase both of hydrophobic cell surface and cell wall polysaccharides, that explain the bigger adhesion capability of the resistant strain. 40 .
Moreover, as overviewed by Ramage et al., 41 the fungal biofilm eradication represents a crucial problem related to a multifactorial resistance mechanisms including extracellular matrix presence, efflux pumps activity and the cell density.
Since the strong clinical impact of biofilm, further studies, involving molecular mechanisms on biofilm formation, quorum sensing, expression of resistance gene or possible gene resistant transfer are required to better understand the link between biofilm lifestyle and drug resistance.
In conclusion, the changing of Candida species epidemiology, together with the increase of resistant strains and their ability to form biofilm, underline the need to monitor the incidence of new emerging Candida species and the antifungal susceptibility profile for a correct management of the infections.
